Fig. 4

Kaplan–Meier survival curves of the relapse-free survival for GC-TLS formation in patients with ESCC. A. The group who received neoadjuvant chemotherapy (survival rate at 36 months: 86.7%, and 75.5%, respectively). B. The group without neoadjuvant chemotherapy (survival rate at 36 months: 61.1%, and 45.5%, respectively). C. The group who received neoadjuvant chemotherapy with clinical stage 0, I, and II (survival rate at 36 months: 61.4%, and 55.6%, respectively). D. The group who received neoadjuvant chemotherapy with clinical stage III, IVa (survival rate at 36 months: 37.1%, and 65.0%, respectively). E. Hazard ratios were calculated by grouping patients according to clinical progression (III, IVa and 0, I, II) as forest plots. HR, hazard ratio; p < 0.05, statistically significant